Clinical trialNCT02285439CompletedPhase 1,PHASE2Interventional

Study of MEK162 for Children With Low-Grade Gliomas

SponsorChildren's Hospital Los AngelesEnrollment105Low-Grade GliomasMalignant Neoplasms, BrainSoft Tissue Neoplasms

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to study the drug MEK162 in children with a brain tumor call low-grade glioma, as well as in children with other tumors in which a specific growth signal is abnormally turned on. The main questions it aims to answer are: What is the correct dose of MEK162 in children? What are the side effects of MEK162 in children? Is MEK162 effective in children with low-grade glioma? Participants on the study receive MEK162 by mouth twice daily for up to 2 years.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Nathan Robison, MD
CHLA
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Hospital of Alabama
Birmingham, Alabama, United States
Children'S Hospital Los Angeles
Los Angeles, California, United States
Children'S Hospital of Colorado
Aurora, Colorado, United States
Children'S National Heath Systems
Washington D.C., District of Columbia, United States
Nicklaus Children'S Hospital
Miami, Florida, United States
Children'S Healthcare of Atlanta
Atlanta, Georgia, United States
Johns Hopkins University
Baltimore, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Children'S Hospitals and Clinics of Minnesota-Minneapolis
Minneapolis, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
New York University
New York, New York, United States
Oregon Health and Science University
Portland, Oregon, United States
University of Texas Southwestern Medical
Dallas, Texas, United States
Texas Children'S Hospital
Houston, Texas, United States
Seattle Children'S Hospital
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

MEK162

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 4 May 2016
Primary completion: 2 Nov 2022
Completion: 1 Aug 2025
Last update posted: 7 Oct 2025
Registered enrollment: 105
Registry id: NCT02285439

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.